AZN vs LQDA
AstraZeneca PLC vs Liquidia Corporation — AI-powered side-by-side comparison
AZN
AstraZeneca PLC
56
Watch
VS
LQDA
Liquidia Corporation
68
Buy
| Metric | AZN | LQDA |
|---|
| AI Score |
56
|
68
|
| Price |
$158.74
|
$88.09
|
| P/E Ratio |
23.81×
|
368.26×
|
| ROE |
21.1%
|
-154.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
79.3%
|
91.8%
|
| Debt / Equity |
0.64×
|
1.70×
|
| Dividend Yield |
1.3%
|
0.0%
|
| RSI (14) |
33.8
|
55.0
|
| Beta |
0.211
|
0.572
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for AZN versus LQDA.
LQDA leads by 12 points.
LQDA scores 68/100 (Buy) versus AZN at 56/100 (Watch).
AZN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.94 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 21.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.9% YoY — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
LQDA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 1936.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 362.9 is expensive by classic value standards — Value
- Price-to-book of 12.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical